1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
615D22D55679C03F3002585BC0066139D
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-MSL-engagements-related-on-label-data?opendocument
18
19opendocument
203.237.254.197
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Medical Science Liaison

MSL Engagements Related to On-Label Data

ID: 5626


Features:

3 Info Graphics

7 Data Graphics

20 Metrics

2 Narratives


Pages/Slides: 16


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "MSL Engagements Related to On-Label Data"

STUDY OVERVIEW

As the role of Medical Science Liaisons (MSLs) continues to evolve, pharma companies must continuously re-evaluate and update their guidelines for scientific interactions with Healthcare Practitioners (HCPs) and thought-leaders.

Best Practices conducted this study to provide Medical leaders with insights, as well as the oversight that such engagements occur in a compliant manner. 

KEY TOPICS

  • Study Overview
  • MSL Engagements
  • Auditing MSL Engagements)
KEY METRICS
  • How are MSLs allowed to address thought-leaders with regards to product-related on-label data (i.e. pivotal data in the package insert)?
  • In regards to the current health crisis surrounding COVID-19, can MSLs proactively (not product related) go to their HCPs and discuss ways to engage virtually?
  • How often does your company conduct internal audits in regards to how MSLs engage with thought-leaders?
  • Who conducts such audits in your company?
  • On what systems or files (such as Veeva, etc.) are you conducting audits of thought-leader engagements?

SAMPLE KEY FINDINGS
  • Nearly 80% of companies allow MSLs to speak both proactively and reactively to HCPs regarding on-label data. There is little difference in this regards, whether the MSL is in U.S., Europe or other regions of the world.

METHODOLOGY

Best Practices, LLC engaged 23 leaders from 14 life sciences companies through a benchmarking survey. 74% are for either global groups or those representing specific regions or countries outside the U.S.


Industries Profiled:
Health Care; Pharmaceutical; Biotech; Medical Device; Manufacturing; Biopharmaceutical


Companies Profiled:
Eisai; Puma Biotechnology; AstraZeneca; B. Braun; Boehringer Ingelheim; Vifor Pharma; Mallinckrodt; Dova Pharmaceuticals; Lundbeck; Merck; Novartis; Pfizer; Greenwich Biosciences

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.